All In MedTech

FDA Clearance Tracker · P030052

UROVYSION BLADDER CANCER KIT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jan 24, 2005 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jan 24, 2005

Approved

Time to decision

411 days

Received Dec 10, 2003. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P030052
Device name
UROVYSION BLADDER CANCER KIT
Applicant location
Des Plaines, IL
Received
Dec 10, 2003
Decided
Jan 24, 2005
Decision
Approved
Supplements
30 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE UROVYSION BLADDER CANCER KIT. THE DEVICE IS INDICATED FOR: THE UROVYSION BLADDER CANCER KIT (UROVYSION KIT) IS DESIGNED TO DETECT ANEUPLOIDY FOR CHROMOSOMES 3, 7, 17 AND LOSS OF THE 9P21 LOCUS VIA FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN URINE SPECIMENS FROM PERSONS WITH HEMATURIA SUSPECTED OF HAVING BLADDER CANCER. RESULTS FROM THE UROVYSION KIT ARE INTENDED FOR USE, IN CONJUNCTION WITH AND NOT IN LIEU OF CURRENT STANDARD DIAGNOSTIC PROCEDURES, AS AN AID FOR INITIAL DIAGNOSIS OF BLADDER CARCINOMA IN PATIENTS WITH HEMATURIA AND SUBSEQUENT MONITORING FOR TUMOR RECURRENCE IN PATIENTS PREVIOUSLY DIAGNOSED WITH BLADDER CANCER.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • We could not check whether this was the first decision under its product code.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott Molecular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.